U.S. Food, 2018-10-22: October 2018 FDA letter to firms marketing unapproved prescription local anesthetics, requiring labeling that warns of methemoglobinemia.
This letter concerns unapproved prescription drug products containing local anesthetics, which are now or have previously been manufactured, repackaged, relabeled, or distributed by your firm.
1
U.S. Food, 2018-10-22: October 2018 FDA letter to firms marketing unapproved prescription local anesthetics, requiring labeling that warns of methemoglobinemia. C2. This PDF embeds a non-standard font encoding, so the extracted text is shifted by a constant offset; decoding it yields the date line 'October 22, 2018' and the quoted opening sentence. Treat the quote as read from the decoded text, hence confidence MEDIUM. A verification pass that extracts this PDF with pdftotext will return the shifted characters and not match the quote; that is a font-encoding artefact of the file, not a misquotation – the page renders correctly in a PDF viewer. Names benzocaine, lidocaine and tetracaine as examples of active ingredients in these unapproved products and ties them to the methemoglobinemia risk; cites the 2011 marketed-unapproved-drugs compliance policy guide. Study type: regulatory record.
